Visus Therapeutics Appoints Industry Leaders Tracy Valorie and Dwight Moxie to Board of Directors
Visus Therapeutics announced the appointments of Tracy Valorie, former Senior Vice President and General Manager, US Ophthalmology Rx and Surgical at Bausch + Lomb; and Dwight Moxie, Senior Vice President, General Counsel and Corporate Secretary at Revance Therapeutics to its Board of Directors.
“I am very pleased to welcome Tracy Valorie and Dwight Moxie to Visus Therapeutics’ Board of Directors,” Ben Bergo, co-founder and chief executive officer at Visus Therapeutics, said in a company news release. “Both of these renowned leaders possess expertise across many industries and will be invaluable as we continue to grow our portfolio of novel compounds and advance our lead program, Brimochol, in development for the treatment of presbyopia. I look forward to their strategic insights and contributions to achieve our mission of dramatically improving patients’ lives by developing differentiated best-in-class ophthalmic therapies.”
Ms. Valorie brings deep expertise with 25 years of experience in the pharmaceutical and biotech industries spanning strategic business counsel, commercial development, brand and customer marketing, and clinical development and research. Ms. Valorie previously served as Senior Vice President and General Manager of US Ophthalmology Rx and Surgical at Bausch + Lomb. Prior to that, she held numerous leadership positions at Pfizer where she led commercial development for the company’s global Ophthalmology Franchise, including Xalatan and Xalacom for glaucoma.
Mr. Moxie is the General Counsel, Senior Vice President and Corporate Secretary at Revance Therapeutics. Mr. Moxie leads legal, governance and compliance for the company, and brings more than two decades of experience in the biopharmaceutical and healthcare sectors, advising and supporting companies developing and commercializing novel drugs. Previously, he served as the Vice President, Deputy General Counsel at Ultragenyx and held various legal counsel positions at Allergan and GlaxoSmithKline.
Capital Markets Day in New York City – August 31, 2021
The company previously announced that it will host its first Capital Markets Day for investors, analysts and media on August 31, 2021, from 10:00 a.m. to 2:00 p.m. ET at Convene, 530 Fifth Avenue in New York City. The Capital Markets Day will include presentations from Ben Bergo, co-founder and chief executive officer, Rhett Schiffman, MD, MS, MHSA, co-founder, chief medical officer and head of research and development, and Carey Powers, vice president of marketing, as well as key opinion leaders in ophthalmology and optometry with a focus on the company’s development pipeline and emerging advances in the treatment of presbyopia and other ophthalmic conditions. A live webcast of the presentation and question and answer sessions will be accessible under “Events & Presentations” in the News page of the company’s website at www.visustx.com. To register for the event, please visit the Visus 2021 Capital Markets Day registration site.